Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71.

H. Schwarz,J. Ihle,E. Wecker,P. Fischinger,H. Thiel,D. Bolognesi,W. Schäfer

DOI: https://doi.org/10.1016/0042-6822(81)90358-5

IF: 3.513

1981-06-01

Virology

Abstract:

What problem does this paper attempt to address?

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

J. Peng,W. Tang,H. Bao,S. Mo,X. Ma,R. Liu,X. Chen,S. Wu,Y. Li,L. Zhang,F. Liu,X. Wu,Y. Shao,S. Cai

DOI: https://doi.org/10.1016/j.annonc.2021.08.914

IF: 51.769

2021-01-01

Annals of Oncology

Abstract:Previous studies on liquid biopsy-based detection of advanced colorectal adenoma (advCRA) and early stage adenocarcinoma (CRC) were limited by low sensitivity. To this end, we performed a prospective study and established an integrated model using multiple fragmentomic profiles of plasma cell-free DNA (cfDNA) for accurately and cost-effectively detecting stage 0/I CRC and advCRA. This study enrolled a total of 621 participants, including 298 CRC patients (34 stage 0, 264 stage I), 92 advCRA patients and 231 healthy controls. Plasma cfDNA samples were prepared for low coverage whole-genome sequencing (∼5X). Participants were randomly divided into a training cohort (N = 310) and a test cohort (N = 311). An ensemble stacked model differentiating healthy controls from advCRA/CRC patients was trained using four machine learning models and five cfDNA fragmentomic features, including fragment size distribution and ratio, end and breakpoint motif, and copy number alteration, which was then validated in the test cohort. Our model showed an Area Under the Curve (AUC) of 0.988 for differentiating advCRA/CRC patients from healthy individuals. The model performed even better for identifying CRC patients (AUC 0.990) compared to advCRA patients (AUC 0.982). At 94.8% specificity, the sensitivities for detecting advCRA and CRC reached 95.7% and 98.0% (stage 0: 94.1%; stage I: 98.5%), respectively. Promisingly, the detection sensitivity has reached 100% and 97.6% in CRC patients with negative fecal occult or CEA blood test results, respectively. In advCRA subgroup, our model showed high sensitivities for detecting different grades of dysplasia (high: 91.3%, low: 100%) and for pedunculated (92.9%) or sessile adenoma (96.9%). Finally, our model maintained promising performances (mean AUC: 0.985, 92.6% sensitivity at 94.8% specificity) even when sequencing depth was downsampled to 1X. Our integrated predictive model using plasma cfDNA fragmentomic profiles demonstrated an unprecedented detection sensitivity for advCRA and very early-stage CRC, shedding light on more accurate non-invasive colorectal cancer screening in clinical practice.
Multi-Dimensional Cell-free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer

Siwei Wang,Fanchen Meng,Ming Li,Hua Bao,Xin Chen,Meng Zhu,Rui Liu,Xiuxiu Xu,Shanshan Yang,Xue Wu,Yang Shao,Lin Xu,Rong Yin

DOI: https://doi.org/10.1164/rccm.202109-2019oc

IF: 24.7

2022-11-08

American Journal of Respiratory and Critical Care Medicine

Abstract:Rationale: Cell-free DNA (cfDNA) analysis holds promise for early detection of lung cancer and benefits patients with higher survival. However, the detection sensitivity of previous cfDNA-based studies was still low to suffice for clinical use, especially for early-stage tumors. Objectives: Establish an accurate and affordable approach for early-stage lung cancer detection by integrating cfDNA fragmentomics and machine learning models. Methods: This study included 350 participants without cancer and 432 participants with cancer. The participants' plasma cfDNA samples were profiled by whole-genome sequencing. Multiple cfDNA features and machine learning models were compared in the training cohort to achieve an optimal model. Model performance was evaluated in three validation cohorts. Measurements and Main Results: A stacked ensemble model integrating five cfDNA features and five machine learning algorithms constructed in the training cohort (cancer: 113; healthy: 113) outperformed all the models built on individual feature-algorithm combinations. This integrated model yielded superior sensitivities of 91.4% at 95.7% specificity for cohort validation I (area under the curve [AUC], 0.984), 84.7% at 98.6% specificity for validation II (AUC, 0.987), and 92.5% at 94.2% specificity for additional validation (AUC, 0.974), respectively. The model's high performance remained consistent when sequencing depth was down to 0.5× (AUC, 0.966-0.971). Furthermore, our model is sensitive to identifying early pathological features (83.2% sensitivity for stage I, 85.0% sensitivity for <1 cm tumor at the 0.66 cutoff). Conclusions: We have established a stacked ensemble model using cfDNA fragmentomics features and achieved superior sensitivity for detecting early-stage lung cancer, which could promote early diagnosis and benefit more patients.

respiratory system,critical care medicine
Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study

Fudong Xu,Chong Wang,Hongxia Li,Bo Yu,Luyuan Chang,Feng Wang,Chaolian Long,Ling Bai,Hanqing Zhao,Nanying Che

DOI: https://doi.org/10.1111/cas.16360

2024-10-28

Abstract:Lung cancer is one of the most prevalent cancers worldwide, yet only approximately 16% of patients are diagnosed in early stage, highlighting the urgent need for novel, highly accurate detection models. In our study, patients with suspected lung cancer or lung disease, as identified through radiographic imaging, along with healthy individuals, were consecutively recruited from Beijing Chest Hospital. Circulating free DNA (cfDNA) was extracted from plasma samples, and low-depth whole-genome sequencing was performed to identify fragmentomic features for model construction. A total of 265 participants were prospectively enrolled, comprising 124 lung cancer patients and 141 noncancer individuals. The model we developed was based on four cfDNA fragmentation characteristics, including 20-bp breakpoint nucleotides motif, fragmentation size coverage, fragmentation size distribution, and copy number variation. In an independent test cohort, the model achieved an area under the curve (AUC) of 0.861 (95% CI: 0.781-0.942) and demonstrated a sensitivity of 70% (95% CI: 53.5%-83.4%) at a specificity of 89.4% (95% CI: 76.9%-96.5%). Notably, the model was also effective in detecting early-stage cancer, with an AUC of 0.808 (95% CI: 0.69-0.925). In summary, our lung cancer detection model shows strong screening capabilities by leveraging four cfDNA fragmentation characteristics, exhibiting robust performance in early cancer diagnosis.
Circulating cell-free DNA sequencing for early detection of lung cancer

Ruyue Xue,Lu Yang,Meijia Yang,Fangfang Xue,Lifeng Li,Manjiao Liu,Yong Ren,Yu Qi,Jie Zhao

DOI: https://doi.org/10.1080/14737159.2023.2224504

Abstract:Introduction: Lung cancer is a leading cause of death in patients with cancer. Early diagnosis is crucial to improve the prognosis of patients with lung cancer. Plasma circulating cell-free DNA (cfDNA) contains comprehensive genetic and epigenetic information from tissues throughout the body, suggesting that early detection of lung cancer can be done non-invasively, conveniently, and cost-effectively using high-sensitivity techniques such as sequencing. Areas covered: In this review, we summarize the latest technological innovations, coupled with next-generation sequencing (NGS), regarding genomic alterations, methylation, and fragmentomic features of cfDNA for the early detection of lung cancer, as well as their clinical advances. Additionally, we discuss the suitability of study designs for diagnostic accuracy evaluation for different target populations and clinical questions. Expert opinion: Currently, cfDNA-based early screening and diagnosis of lung cancer faces many challenges, such as unsatisfactory performance, lack of quality control standards, and poor repeatability. However, the progress of several large prospective studies employing epigenetic features has shown promising predictive performance, which has inspired cfDNA sequencing for future clinical applications. Furthermore, the development of multi-omics markers for lung cancer, including genome-wide methylation and fragmentomics, is expected to play an increasingly important role in the future.
Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.

Zichen Jiao,Xiaoqiang Zhang,Yulong Xuan,Xiaoming Shi,Zirui Zhang,Ao Yu,Ningyou Li,Shanshan Yang,Xiaofeng He,Gefei Zhao,Ruowei Yang,Jianqun Chen,Xuxiaochen Wu,Xiaoxi Chen,Hua Bao,Fufeng Wang,Wei Ren,Hongwei Liang,Qihan Chen,Tao Wang

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.4054

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:4054 Background: In this study, we developed a stacked ensemble model that leverages cell-free DNA (cfDNA) fragmentation for the early detection of esophageal squamous cell carcinoma (ESCC). The model combined four fragmentomics features obtained from whole genome sequencing (WGS) and employed four machine learning algorithms. We evaluated the model’s generalizability in an independent validation cohort and an external cohort collected at different center. Additionally, the model’s robustness and repeatability were assessed across low coverage and repeated measured samples. The results underscore the promising potential of our model as an effective strategy for early diagnosis and management of ESCC in clinical settings. Methods: 256 healthy individuals and 243 patients diagnosed with esophageal cancer were enrolled in this study, including 47 healthy participants and 44 patients in the external cohort. Plasma samples from all participants were profiled by whole-genome sequencing (WGS). Fragmentomic features encompassed copy number variation (CNV), fragmentation size coverage (FSC), fragmentation size distribution (FSD), and nucleosome positioning (NP) were incorporated alongside machine learning models to develop an optimized classification model. The model generated a cancer score ranging from 0 to 1 for each cancer and noncancer sample, with a score closer to 1 indicating a higher probability of cancer. The performance of this model was assessed using an independent validation cohort and an external cohort, and model’s robustness and reproducibility were examined. Results: A stacked ensemble model was developed by integrating four cfDNA features and four machine learning algorithms. This integrated model exhibiting remarkable sensitivity of 91.8% (89/97) and specificity of 98.1% (102/104), and AUC of 0.986 in the independent validation cohorts using the cut-off of 0.69 selected at a specificity level of 98% (105) in the training cohort. The external cohort demonstrated a sensitivity of 86.4% (38/44) and a specificity of 95.7% (45/47) with the same cut-off. The model's performance remained consistent even at low sequencing coverage depths of 0.5× (AUC 0.978), providing valuable insights into the resilience and stability of our methodology and ascertained its practical applicability in scenarios with limited sequencing resources or constraints. Furthermore, our model demonstrated sensitivity in identifying early pathological features, with a sensitivity of 94.1% (16/17) for stage I and 91.4% (53/58) for tumors smaller than 3 cm. Conclusions: A stacked ensemble model was implemented in this study, utilizing cfDNA fragmentomics features with exceptional sensitivity for early detection of esophageal squamous cell carcinoma. The anticipated impact of this model is the enhancement of early detection strategies for esophageal cancer in clinical setting.

oncology
Accurate Early Detection and EGFR Mutation Status Prediction of Lung Cancer Using Plasma Cfdna Coverage Patterns: A Proof-of-Concept Study

Zhixin Bie,Yi Ping,Xiaoguang Li,Xun Lan,Lihui Wang

DOI: https://doi.org/10.3390/biom14060716

IF: 6.064

2024-01-01

Biomolecules

Abstract:Lung cancer is a major global health concern with a low survival rate, often due to late-stage diagnosis. Liquid biopsy offers a non-invasive approach to cancer detection and monitoring, utilizing various features of circulating cell-free DNA (cfDNA). In this study, we established two models based on cfDNA coverage patterns at the transcription start sites (TSSs) from 6X whole-genome sequencing: an Early Cancer Screening Model and an EGFR mutation status prediction model. The Early Cancer Screening Model showed encouraging prediction ability, especially for early-stage lung cancer. The EGFR mutation status prediction model exhibited high accuracy in distinguishing between EGFR-positive and wild-type cases. Additionally, cfDNA coverage patterns at TSSs also reflect gene expression patterns at the pathway level in lung cancer patients. These findings demonstrate the potential applications of cfDNA coverage patterns at TSSs in early cancer screening and in cancer subtyping.
Integrated 5-hydroxymethylcytosine and fragmentation signatures as enhanced biomarkers in lung cancer

Xinlei Hu,Kai Luo,Hui Shi,Xiaoqin Yan,Ruichen Huang,Bi Zhao,Jun Zhang,Dan Xie,Wei Zhang

DOI: https://doi.org/10.1186/s13148-022-01233-7

2022-01-24

Abstract:Background: Lung cancer is one of most common cancers worldwide, with a 5-year survival rate of less than 20%, which is mainly due to late-stage diagnosis. Noninvasive methods using 5-hydroxymethylation of cytosine (5hmC) modifications and fragmentation profiles from 5hmC cell-free DNA (cfDNA) sequencing provide an opportunity for lung cancer detection and management. Results: A total of 157 lung cancer patients were recruited to generate the largest lung cancer cfDNA 5hmC dataset, which mainly consisted of 62 lung adenocarcinoma (LUAD), 48 lung squamous cell carcinoma (LUSC) and 25 small cell lung cancer (SCLC) patients, with most patients (131, 83.44%) at advanced tumor stages. A 37-feature 5hmC model was constructed and validated to distinguish lung cancer patients from healthy controls, with areas under the curve (AUCs) of 0.8938 and 0.8476 (sensitivity = 87.50% and 72.73%, specificity = 83.87% and 80.60%) in two distinct validation sets. Furthermore, fragment profiles of cfDNA 5hmC datasets were first explored to develop a 48-feature fragmentation model with good performance (AUC = 0.9257 and 0.822, sensitivity = 87.50% and 78.79%, specificity = 80.65% and 76.12%) in the two validation sets. Another diagnostic model integrating 5hmC signals and fragment profiles improved AUC to 0.9432 and 0.8639 (sensitivity = 87.50% and 83.33%, specificity = 90.30% and 77.61%) in the two validation sets, better than models based on either of them alone and performing well in different stages and lung cancer subtypes. Several 5hmC markers were found to be associated with overall survival (OS) and disease-free survival (DFS) based on gene expression data from The Cancer Genome Atlas (TCGA). Conclusions: Both the 5hmC signal and fragmentation profiles in 5hmC cfDNA data are sensitive and effective in lung cancer detection and could be incorporated into the diagnostic model to achieve good performance, promoting research focused on clinical diagnostic models based on cfDNA 5hmC data.
Distinct Features of Plasma Ultrashort Single-Stranded Cell-Free DNA as Biomarkers for Lung Cancer Detection

Jordan Cheng,Neeti Swarup,Feng Li,Misagh Kordi,Chien-Chung Lin,Szu-Chun Yang,Wei-Lun Huang,Mohammad Aziz,Yong Kim,David Chia,Yu-Min Yeh,Fang Wei,David Zheng,Liying Zhang,Matteo Pellegrini,Wu-Chou Su,David T W Wong

DOI: https://doi.org/10.1093/clinchem/hvad131

IF: 12.114

2023-09-19

Clinical Chemistry

Abstract:Abstract Background Using broad range cell-free DNA sequencing (BRcfDNA-Seq), a nontargeted next-generation sequencing (NGS) methodology, we previously identified a novel class of approximately 50 nt ultrashort single-stranded cell-free DNA (uscfDNA) in plasma that is distinctly different from 167 bp mononucleosomal cell-free DNA (mncfDNA). We hypothesize that uscfDNA possesses characteristics that are useful for disease detection. Methods Using BRcfDNA-Seq, we examined both cfDNA populations in the plasma of 18 noncancer controls and 14 patients with late-stage nonsmall cell lung carcinoma (NSCLC). In comparison to mncfDNA, we assessed whether functional element (FE) peaks, fragmentomics, end-motifs, and G-Quadruplex (G-Quad) signatures could be useful features of uscfDNA for NSCLC determination. Results In noncancer participants, compared to mncfDNA, uscfDNA fragments showed a 45.2-fold increased tendency to form FE peaks (enriched in promoter, intronic, and exonic regions), demonstrated a distinct end-motif-frequency profile, and presented with a 4.9-fold increase in G-Quad signatures. Within NSCLC participants, only the uscfDNA population had discoverable FE peak candidates. Additionally, uscfDNA showcased different end-motif-frequency candidates distinct from mncfDNA. Although both cfDNA populations showed increased fragmentation in NSCLC, the G-Quad signatures were more discriminatory in uscfDNA. Compilation of cfDNA features using principal component analysis revealed that the first 5 principal components of both cfDNA subtypes had a cumulative explained variance of >80%. Conclusions These observations indicate that the distinct biological processes of uscfDNA and that FE peaks, fragmentomics, end-motifs, and G-Quad signatures are uscfDNA features with promising biomarker potential. These findings further justify its exploration as a distinct class of biomarker to augment pre-existing liquid biopsy approaches.

medical laboratory technology
[Development and Validation of Predictive Models for Esophageal Squamous Cell Carcinoma and Its Precancerous Lesions Using Terminal Motif Analysis in Circulating Cell-Free DNA].

S Y Liu,Z Q Li,L Z Dou,Y M Zhang,Y Liu,Y M Liu,Y Ke,X D Liu,H R Wu,J T Chu,S He,G Q Wang

DOI: https://doi.org/10.3760/cma.j.cn112152-20231207-00353

2024-01-01

Abstract:Objectives: To develop and validate predictive models for esophageal squamous cell carcinoma (ESCC) using circulating cell-free DNA (cfDNA) terminal motif analysis. The goal was to improve the non-invasive detection of early-stage ESCC and its precancerous lesions. Methods: Between August 2021 and November 2022, we prospectively collected plasma samples from 448 individuals at the Department of Endoscopy, Cancer Hospital, Chinese Academy of Medical Sciences for cfDNA extraction, library construction, and sequencing. We analyzed 201 cases of ESCC, 46 high-grade intraepithelial neoplasia (HGIN), 46 low-grade intraepithelial neoplasia (LGIN), 176 benign esophageal lesions, and 29 healthy controls. Participants, including ESCC patients and control subjects, were randomly assigned to a training set (n=284) and a validation set (n=122). The training cohort underwent z-score normalization of cfDNA terminal motif matrices and a selection of distinctive features differentiated ESCC cases from controls. The random forest classifier, Motif-1 (M1), was then developed through principal component analysis, ten-fold cross-validation, and recursive feature elimination. M1's efficacy was then validated in the validation and precancerous lesion sets. Subsequently, individuals with precancerous lesions were included in the dataset and participants were randomly allocated to newly formed training (n=243), validation (n=105), and test (n=150) cohorts. Using the same procedure as M1, we trained the Motif-2 (M2) random forest model with the training cohort. The M2 model's accuracy was then confirmed in the validation cohort to establish the optimal threshold and further tested by performing validation in the test cohort. Results: We developed two cfDNA terminal motif-based predictive models for ESCC and associated precancerous conditions. The first model, M1, achieved a sensitivity of 90.0%, a specificity of 77.4%, and an area under the curve (AUC) of 0.884 in the validation cohort. For LGIN, HGIN, and T1aN0 stage ESCC, M1's sensitivities were 76.1%, 80.4%, and 91.2% respectively. Notably, the sensitivity for jointly predicting HGIN and T1aN0 ESCC reached 85.0%. Both the predictive accuracy and sensitivity increased in line with the cancer's progression (P＜0.001). The second model, M2, exhibited a sensitivity of 87.5%, a specificity of 77.4%, and an AUC of 0.857 in the test cohort. M2's sensitivities for detecting precancerous lesions and ESCC were 80.0% and 89.7%, respectively, and it showed a combined sensitivity of 89.4% for HGIN and T1aN0 stage ESCC. Conclusions: Two predictive models based on cfDNA terminal motif analysis for ESCC and its precancerous lesions are developed. They both show high sensitivity and specificity in identifying ESCC and its precancerous stages, indicating its potential for early ESCC detection.
Detection and characterization of lung cancer using cell-free DNA fragmentomes

Dimitrios Mathios,Jakob Sidenius Johansen,Stephen Cristiano,Jamie E. Medina,Jillian Phallen,Klaus R. Larsen,Daniel C. Bruhm,Noushin Niknafs,Leonardo Ferreira,Vilmos Adleff,Jia Yuee Chiao,Alessandro Leal,Michael Noe,James R. White,Adith S. Arun,Carolyn Hruban,Akshaya V. Annapragada,Sarah Østrup Jensen,Mai-Britt Worm Ørntoft,Anders Husted Madsen,Beatriz Carvalho,Meike de Wit,Jacob Carey,Nicholas C. Dracopoli,Tara Maddala,Kenneth C. Fang,Anne-Renee Hartman,Patrick M. Forde,Valsamo Anagnostou,Julie R. Brahmer,Remond J. A. Fijneman,Hans Jørgen Nielsen,Gerrit A. Meijer,Claus Lindbjerg Andersen,Anders Mellemgaard,Stig E. Bojesen,Robert B. Scharpf,Victor E. Velculescu

DOI: https://doi.org/10.1038/s41467-021-24994-w

IF: 16.6

2021-08-20

Nature Communications

Abstract:Abstract Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for cancer detection and intervention. Here, we use a machine learning model for detecting tumor-derived cfDNA through genome-wide analyses of cfDNA fragmentation in a prospective study of 365 individuals at risk for lung cancer. We validate the cancer detection model using an independent cohort of 385 non-cancer individuals and 46 lung cancer patients. Combining fragmentation features, clinical risk factors, and CEA levels, followed by CT imaging, detected 94% of patients with cancer across stages and subtypes, including 91% of stage I/II and 96% of stage III/IV, at 80% specificity. Genome-wide fragmentation profiles across ~13,000 ASCL1 transcription factor binding sites distinguished individuals with small cell lung cancer from those with non-small cell lung cancer with high accuracy (AUC = 0.98). A higher fragmentation score represented an independent prognostic indicator of survival. This approach provides a facile avenue for non-invasive detection of lung cancer.

multidisciplinary sciences
Fractal analysis of narwhal space use patterns.

K. Laidre,M. Heide‐Jørgensen,Miles L. Logsdon,R. Hobbs,R. Dietz,G. Vanblaricom

DOI: https://doi.org/10.1016/J.ZOOL.2003.09.001

IF: 2.027

2004-03-16

Zoology

Abstract:
Non-invasive Lung Cancer Diagnosis and Prognosis Based on Multi-Analyte Liquid Biopsy.

Kezhong Chen,Jianlong Sun,Heng Zhao,Ruijingfang Jiang,Jianchao Zheng,Zhilong Li,Jiaxi Peng,Haifeng Shen,Kai Zhang,Jin Zhao,Shida Zhu,Yuying Wang,Fan Yang,Jun Wang

DOI: https://doi.org/10.1186/s12943-021-01323-9

IF: 37.3

2021-01-01

Molecular Cancer

Abstract:Chest LDCT provides an effective approach for lung cancer screening, yet has been found to generate a large number of false positives during practice due to excessive diagnosis of pulmonary lesions of indeterminate clinical significance. In this study, we performed comprehensive genetic and epigenetic profiling of cfDNA from lung cancer patients and individuals bearing benign lung lesions, using ultra-deep targeted sequencing and targeted bisulfite sequencing. We found that cfDNA mutation profile alone has relatively limited power in distinguishing malignant from benign plasma, while cfDNA methylation profiling showed a better performance for classification of the two groups and combination of genetic and epigenetic features of cfDNA along with serum protein marker further improved the classification accuracy. We also identified novel methylation-based prognostic markers and showed that an integrated model that combined cfDNA mutational status and methylation-based prognostic markers improved prediction for lung cancer survival. Our results highlight the potential of the multi-analyte assay for non-invasive lung cancer diagnosis and prognosis.
Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis

Guangxi Wang,Mantang Qiu,Xudong Xing,Juntuo Zhou,Hantao Yao,Mingru Li,Rong Yin,Yan Hou,Yang Li,Shuli Pan,Yuqing Huang,Fan Yang,Fan Bai,Honggang Nie,Shuangshuang Di,Limei Guo,Zhu Meng,Jun Wang,Yuxin Yin

DOI: https://doi.org/10.1126/scitranslmed.abk2756

IF: 17.1

2022-02-02

Science Translational Medicine

Abstract:Lung cancer is the leading cause of cancer mortality, and early detection is key to improving survival. However, there are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. Here, we performed single-cell RNA sequencing of different early-stage lung cancers and found that lipid metabolism was broadly dysregulated in different cell types, with glycerophospholipid metabolism as the most altered lipid metabolism–related pathway. Untargeted lipidomics was carried out in an exploratory cohort of 311 participants. Through support vector machine algorithm-based and mass spectrum–based feature selection, we identified nine lipids (lysophosphatidylcholines 16:0, 18:0, and 20:4; phosphatidylcholines 16:0–18:1, 16:0–18:2, 18:0–18:1, 18:0–18:2, and 16:0–22:6; and triglycerides 16:0–18:1–18:1) as the features most important for early-stage cancer detection. Using these nine features, we developed a liquid chromatography–mass spectrometry (MS)–based targeted assay using multiple reaction monitoring. This target assay achieved 100.00% specificity on an independent validation cohort. In a hospital-based lung cancer screening cohort of 1036 participants examined by low-dose computed tomography and a prospective clinical cohort containing 109 participants, the assay reached more than 90.00% sensitivity and 92.00% specificity. Accordingly, matrix-assisted laser desorption/ionization MS imaging confirmed that the selected lipids were differentially expressed in early-stage lung cancer tissues in situ. This method, designated as Lung Cancer Artificial Intelligence Detector, may be useful for early detection of lung cancer or large-scale screening of high-risk populations for cancer prevention.

cell biology,medicine, research & experimental
Early detection of colorectal adenocarcinoma by decoding epigenetic and DNA fragmentation fingerprints of plasma cell-free DNA.

Li Suxing,Tiancheng Han,Shunli Yang,Dan Liu,Peiyao Nie,Fang Lv,Shuying He,Ying Yang,Yulong LI,Jianing Yu,Yuanyuan Hong,Yu S. Huang,Weizhi Chen,Zhengqi Wen

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.3550

IF: 45.3

2022-06-04

Journal of Clinical Oncology

Abstract:3550 Background: Cell-free DNA (cfDNA) methylation, fragmentation patterns, chromosome instability, and chromatin accessiblity have been previously shown to be valid plasma biomarkers for non-invasive cancer detection. However, conventional whole-genome bisulfite sequencing (WGBS) is unable to simultaneously profile all these biomarkers due to bisulfite-induced DNA damages. Here we developed a machine learning approach to comprehensively integrate multiple types of cancer genomic markers from enzyme-conversion-based low-pass whole-methylome sequencing (WMS) of plasma cfDNA to non-invasively detect colorectal adenocarcinoma. Methods: Plasma cfDNA sampels from 215 colorectal adenocarcinoma patients and 568 healthy individuals were collected and were split into the discovery and independent testing cohort. The discovery cohort includes 150 cancer patients and 398 healthy individuals and the independent testing cohort includes 65 cancer patients and 170 healthy individuals. Whole methylome sequencing (WMS) libraries were generated from enzymatically converted cfDNA and were subsequently paired-end sequenced at ̃2X coverage. The genome-wide methylation density, fragmentation fingerprints, chromosome instability, and chromatin accessibility were extracted from the WMS data and individually modelled via machine learning methods such as SVM, LR, GBDT, random forest. The final predictive model is an ensemble model integrating all uni-modal models. All models were trained and fitted on the discovery cohort. Results: Data of different modalities provide complementary information in separating the cancer patients from the healthy individuals. Unsupervised clustering of the individuals showed clear separation between cancer patients and healthy individuals. The final predictive model achieved AUC =0.982 in the discovery cohort and AUC =0.9664 in the independent testing cohort. Under a specificity of 94.71% (CI: 90% - 98.82%), sensitivity was 78.46% (CI: 60% - 92.31%) in the independent testing cohort. Separating the cancer patients into different stages, we found that the detection power is usuaul lower for early-stage cancer patients. Conclusions: These results demonstrate the first proof of principle on the feasibility of integrating multiple genomic cancer markers to non-invasively detect colorectal adenocarcinoma from WMS plasma cell-free DNA. A large prospective cohort study is planned to further validate its clinical performance.

oncology
Non-invasive detection of esophageal carcinoma by integrative analysis of low-pass whole methylome sequencing of plasma cell-free DNA.

Dan Liu,Bin Jiang,Weizhi Chen,Peiyao Nie,Hongyu Xie,Tiancheng Han,Shunli Yang,Yu S. Huang,Fang Lv,Shuying He,Ying Yang,Yulong LI,Yuanyuan Hong,Jianing Yu

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.4067

IF: 45.3

2022-06-04

Journal of Clinical Oncology

Abstract:4067 Background: Cell-free DNA (cfDNA) methylation, fragmentation patterns, chromosome instability, and chromatin accessiblity have been previously shown to be valid plasma biomarkers for non-invasive cancer detection. However, conventional whole-genome bisulfite sequencing (WGBS) is unable to simultaneously profile all these biomarkers due to bisulfite-induced DNA damages. Here we developed a machine learning approach to comprehensively integrate multiple types of cancer genomic markers from enzyme-conversion-based low-pass whole-methylome sequencing (WMS) of plasma cfDNA to non-invasively detect esophageal carcinoma. Methods: Plasma cfDNA sampels from 85 patients and 568 healthy individuals were collected and were split into the discovery and independent testing cohort. The discovery cohort includes 60 cancer patients and 398 healthy individuals and the independent testing cohort includes 25 cancer patients and 170 healthy individuals. Whole methylome sequencing (WMS) libraries were generated from enzymatically converted cfDNA and were subsequently paired-end sequenced at ̃2X coverage. The genome-wide methylation density, fragmentation fingerprints, chromosome instability, and chromatin accessibility were extracted from the WMS data and individually modelled via machine learning methods such as SVM, LR, GBDT, random forest. The final predictive model is an ensemble model integrating all uni-modal models. All models were trained and fitted on the discovery cohort. Results: Data of different modalities provide complementary information in separating the cancer patients from the healthy individuals. Unsupervised clustering of the individuals showed clear separation between cancer patients and healthy individuals. The final predictive model achieved AUC =96.25% in the discovery cohort and AUC =91.15% in the independent testing cohort. Under a specificity of 95.29% (CI: 87.64% - 100.00%), sensitivity was 72.00% (CI: 56.00% - 92.00%) in the independent testing cohort. Separating the cancer patients into different stages, we found that the detection power is usuaul lower for early-stage cancer patients. Conclusions: These results demonstrate the first proof of principle on the feasibility of integrating multiple genomic cancer markers to non-invasively detect esophageal carcinoma from WMS plasma cell-free DNA. A large prospective cohort study is planned to further validate its clinical performance.

oncology
Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization

Fenglong Bie,Zhijie Wang,Yulong Li,Wei Guo,Yuanyuan Hong,Tiancheng Han,Fang Lv,Shunli Yang,Suxing Li,Xi Li,Peiyao Nie,Shun Xu,Ruochuan Zang,Moyan Zhang,Peng Song,Feiyue Feng,Jianchun Duan,Guangyu Bai,Yuan Li,Qilin Huai,Bolun Zhou,Yu S. Huang,Weizhi Chen,Fengwei Tan,Shugeng Gao

DOI: https://doi.org/10.1038/s41467-023-41774-w

IF: 16.6

2023-09-27

Nature Communications

Abstract:Abstract Multimodal epigenetic characterization of cell-free DNA (cfDNA) could improve the performance of blood-based early cancer detection. However, integrative profiling of cfDNA methylome and fragmentome has been technologically challenging. Here, we adapt an enzyme-mediated methylation sequencing method for comprehensive analysis of genome-wide cfDNA methylation, fragmentation, and copy number alteration (CNA) characteristics for enhanced cancer detection. We apply this method to plasma samples of 497 healthy controls and 780 patients of seven cancer types and develop an ensemble classifier by incorporating methylation, fragmentation, and CNA features. In the test cohort, our approach achieves an area under the curve value of 0.966 for overall cancer detection. Detection sensitivity for early-stage patients achieves 73% at 99% specificity. Finally, we demonstrate the feasibility to accurately localize the origin of cancer signals with combined methylation and fragmentation profiling of tissue-specific accessible chromatin regions. Overall, this proof-of-concept study provides a technical platform to utilize multimodal cfDNA features for improved cancer detection.

multidisciplinary sciences
Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling

Wei Guo,Xin Chen,Rui Liu,Naixin Liang,Qianli Ma,Hua Bao,Xiuxiu Xu,Xue Wu,Shanshan Yang,Yang Shao,Fengwei Tan,Qi Xue,Shugeng Gao,Jie He

DOI: https://doi.org/10.1016/j.ebiom.2022.104131

IF: 11.205

2022-07-01

EBioMedicine

Abstract:BACKGROUND: Early diagnosis benefits lung cancer patients with higher survival, but most patients are diagnosed after metastasis. Although cell-free DNA (cfDNA) analysis holds promise, its sensitivity for detecting early-stage lung cancer is unsatisfying. We leveraged cfDNA fragmentomics to develop a predictive model for invasive stage I lung adenocarcinoma (LUAD).METHODS: 292 stage I LUAD patients from three medical centers were included together with 230 healthy controls whose plasma cfDNA samples were profiled by whole-genome sequencing (WGS). Multiple cfDNA fragmentomic motif features and machine learning models were compared in the training cohort to select the best model. Model performance was assessed in the internal and external validation cohorts and an additional dataset.FINDINGS: A logistic regression model using the 6bp-breakpoint-motif feature was selected. It yielded 98·0% sensitivity and 94·7% specificity in the internal validation cohort [Area Under the Curve (AUC): 0·985], while 92·5% sensitivity and 90·0% specificity were achieved in the external validation cohort (AUC: 0·954). It is sensitive for early-stage (100% sensitivity for minimally invasive adenocarcinoma, MIA) and <1 cm (92·9%-97·7% sensitivity) tumors. The predictive power remained high when reducing sequencing depth to 0·5× (AUC: 0·977 and 0·931 for internal and external cohorts).INTERPRETATION: Here we have established a cfDNA breakpoint motif-based model for detecting early-stage LUAD, including MIA and very small-size tumors, shedding light on early cancer diagnosis in clinical practice.FUNDING: National Key R&D Program of China; National Natural Science Foundation of China; CAMS Initiative for Innovative Medicine; Special Research Fund for Central Universities, Peking Union Medical College; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences; Beijing Hope Run Special Fund of Cancer Foundation of China.

medicine, research & experimental
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Hua Bao,Zheng Wang,Xiaoji Ma,Wei Guo,Xiangyu Zhang,Wanxiangfu Tang,Xin Chen,Xinyu Wang,Yikuan Chen,Shaobo Mo,Naixin Liang,Qianli Ma,Shuyu Wu,Xiuxiu Xu,Shuang Chang,Yulin Wei,Xian Zhang,Hairong Bao,Rui Liu,Shanshan Yang,Ya Jiang,Xue Wu,Yaqi Li,Long Zhang,Fengwei Tan,Qi Xue,Fangqi Liu,Sanjun Cai,Shugeng Gao,Junjie Peng,Jian Zhou,Yang Shao

DOI: https://doi.org/10.1186/s12943-022-01594-w

IF: 37.3

2022-06-12

Molecular Cancer

Abstract:Early detection can benefit cancer patients with more effective treatments and better prognosis, but existing early screening tests are limited, especially for multi-cancer detection. This study investigated the most prevalent and lethal cancer types, including primary liver cancer (PLC), colorectal adenocarcinoma (CRC), and lung adenocarcinoma (LUAD). Leveraging the emerging cell-free DNA (cfDNA) fragmentomics, we developed a robust machine learning model for multi-cancer early detection. 1,214 participants, including 381 PLC, 298 CRC, 292 LUAD patients, and 243 healthy volunteers, were enrolled. The majority of patients ( N = 971) were at early stages (stage 0, N = 34; stage I, N = 799). The participants were randomly divided into a training cohort and a test cohort in a 1:1 ratio while maintaining the ratio for the major histology subtypes. An ensemble stacked machine learning approach was developed using multiple plasma cfDNA fragmentomic features. The model was trained solely in the training cohort and then evaluated in the test cohort. Our model showed an Area Under the Curve (AUC) of 0.983 for differentiating cancer patients from healthy individuals. At 95.0% specificity, the sensitivity of detecting all cancer reached 95.5%, while 100%, 94.6%, and 90.4% for PLC, CRC, and LUAD, individually. The cancer origin model demonstrated an overall 93.1% accuracy for predicting cancer origin in the test cohort (97.4%, 94.3%, and 85.6% for PLC, CRC, and LUAD, respectively). Our model sensitivity is consistently high for early-stage and small-size tumors. Furthermore, its detection and origin classification power remained superior when reducing sequencing depth to 1× (cancer detection: ≥ 91.5% sensitivity at 95.0% specificity; cancer origin: ≥ 91.6% accuracy). In conclusion, we have incorporated plasma cfDNA fragmentomics into the ensemble stacked model and established an ultrasensitive assay for multi-cancer early detection, shedding light on developing cancer early screening in clinical practice.

oncology,biochemistry & molecular biology
Abstract 3318: Development of a Cfdna Based Trans-Omics Approach for Early Cancer Detection

Yuying Wang,Heng Zhao,Kaijian Ling,Jianchao Zheng,Zhilong Li,Shuangshuang Chen,Jia Li,Chichuan Liu,Guanghui Yang,Hongpo Zhou,Jiaxi Peng,Lili Ye,Liuhong Zeng,Jianlong Sun,Ruijingfang Jiang,Li Deng,Yanzhou Wang,Kezhong Chen,Zhiqing Liang,Fan Yang,Taiping Shi,Mingzhi Ye

DOI: https://doi.org/10.1158/1538-7445.am2019-3318

IF: 11.2

2019-01-01

Cancer Research

Abstract:Circulating tumor DNA (ctDNA) in plasma of cancer patients provides valuable information about the cancer and also holds great promise for non-invasive early cancer detection. Nevertheless, since ctDNA is diluted by circulating cell-free DNA (cfDNA) of noncancerous origins, its detection poses significant challenge, especially during early stage of cancer. Previous studies on early cancer detection have mostly focused on single feature of the ctDNA, namely either cancer driver gene mutations or alterations in the methylome. We have developed a set of experimental and computational tools to measure both genetic and epigenetic signals from ctDNA using next-generation sequencing, aiming to improve its detection. Briefly, cfDNA extracted from cancer patients and healthy individuals were used for targeted deep sequencing as well as targeted bisulfite sequencing. More specifically, duplex-UMI libraries were prepared in order to suppress errors introduced by sequencing and PCR artifacts. Libraries were subsequently captured using a custom designed panel targeting cancer driver gene mutations. Bisulfite sequencing libraries were prepared from single strand cfDNA following bisulfite conversion and captured using a panel targeting gene promoter regions. These methods ensure higher quality of the cfDNA libraries and more sensitive ctDNA detection. A subset of samples also had matched tumor tissue samples sequenced using targeted sequencing and WGBS to validate mutations as well as changes of CpG methylation level found in plasma. All sequencing runs were conducted on the MGIseq platform developed by BGI genomics. To this end, we have developed classification models based on these data using machine learning approaches. Optimal model achieves a sensitivity of 52% in early stage lung cancer, and a sensitivity of 83.3% in ovarian cancer, while holding specificity > 99%. These results hold great potential to be further explored for early cancer detection application. We are currently expanding the study to additional cancer types, especially the ones with high incidence rate and/or poor survival rate in China, such as colorectal cancer and liver cancer.Citation Format: Yuying Wang, Heng Zhao, Kaijian Ling, Jianchao Zheng, Zhilong Li, Shuangshuang Chen, Jia Li, Chichuan Liu, Guanghui Yang, Hongpo Zhou, Jiaxi Peng, Lili Ye, Liuhong Zeng, Jianlong Sun, Ruijingfang Jiang, Li Deng, Yanzhou Wang, Kezhong Chen, Zhiqing Liang, Fan Yang, Taiping Shi, Mingzhi Ye. Development of a cfDNA based trans-omics approach for early cancer detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3318.

Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71.

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Multi-Dimensional Cell-free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer

Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study

Circulating cell-free DNA sequencing for early detection of lung cancer

Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.

Accurate Early Detection and EGFR Mutation Status Prediction of Lung Cancer Using Plasma Cfdna Coverage Patterns: A Proof-of-Concept Study

Integrated 5-hydroxymethylcytosine and fragmentation signatures as enhanced biomarkers in lung cancer

Distinct Features of Plasma Ultrashort Single-Stranded Cell-Free DNA as Biomarkers for Lung Cancer Detection

[Development and Validation of Predictive Models for Esophageal Squamous Cell Carcinoma and Its Precancerous Lesions Using Terminal Motif Analysis in Circulating Cell-Free DNA].

Detection and characterization of lung cancer using cell-free DNA fragmentomes

Fractal analysis of narwhal space use patterns.

Non-invasive Lung Cancer Diagnosis and Prognosis Based on Multi-Analyte Liquid Biopsy.

Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis

Early detection of colorectal adenocarcinoma by decoding epigenetic and DNA fragmentation fingerprints of plasma cell-free DNA.

Non-invasive detection of esophageal carcinoma by integrative analysis of low-pass whole methylome sequencing of plasma cell-free DNA.

Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization

Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling

Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Abstract 3318: Development of a Cfdna Based Trans-Omics Approach for Early Cancer Detection